Loading
Latest filing published 28 Jul 2026 for Swedish Orphan Biovitrum AB (publ), €1.4M.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Norbert Oppitz is a declared insider of Swedish Orphan Biovitrum AB (publ), with filings sourced from Finansinspektionen. Over a trading history stretching from 13 June 2019 to 28 July 2026, the count stands at 5 filings.
In open-market terms, that means 3 purchases worth €4.2M on one side and 1 sale worth €2.7M on the other. Netting one side against the other leaves €1.4M of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 share grant. Since January 2026: 2 purchases and 1 sale on the market.
The median purchase comes to €1.4M.
The newest entry dates from 28 July 2026: an open-market purchase of €1.4M, in Swedish Orphan Biovitrum AB (publ). Filings reach the Finansinspektionen feed a median of 2 days after the trade. The regulation allows three business days to notify a trade (MAR article 19). Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations